https://vimeo.com/440626033
Results from the long-awaited E2108 trial showed that, in patients with metastatic breast cancer, local therapy did not improve overall survival (OS) when compared with optimal systemic therapy alone. The addition of locoregional therapy also failed to improve 3-year progression-free survival (PFS). However, recurrence or progression was significantly higher in the systemic arm alone.
With a median follow-up of 59 months, Prof. Seema Ahsan Khan (Feinberg School of Medicine, USA) presented the final follow-up data [1]. There has been a paucity of data about whether surgery and radiation to a breast tumour (local therapy) can prolong OS compared with systemic treatment alone. The goal of E2108 was to determine whether surgery and radiation should become routine practice for patients with stage IV breast cancer.
In total, 390 women with stage IV breast cancer were enrolled and received the optimal systemic treatment based on their tumour biomarker status and their metastatic profile. Of those whose disease responded to initial systemic therapy, 258 women were randomised to either receive continued systemic therapy or to receive surgery and radiation prior to continuing systemic therapy.
With 5 years follow-up, it was evident that there was no OS advantage for local therapy versus systemic therapy alone (68.4% vs 67.9%; HR 1.09; 90% CI 0.80-1.49; P=0.63). Furthermore, locoregional therapy did not improve 3-year PFS (P=0.40). In favour of local therapy, however, recurrence or progression was significantly higher in the systemic arm alone (25.6% vs 10.2%; P=0.003). Patient-reported quality of life, as measured by the FACT-B Trial Outcome Index to score depression, anxiety, and well-being, did not show any advantage for the locoregional therapy arm of the trial.
Prof. Khan compared the results to another trial: "When combined with the results of an earlier trial in Mumbai, India [2], these results tip the scales against the possibility that local therapy to the breast tumour will help women live longer." The Indian trial had a similar design to E2108, and also showed similar results between the two treatment groups.
She concluded: "Based on the results of our study, women who present with a new diagnosis of breast cancer already in stage IV should not be offered surgery and radiation for the primary breast tumour with the expectation of a survival benefit."
- Khan SA, et al. ASCO Virtual Meeting, 29-31 May 2020, Abstract LBA2.
- Badwe R, et al. Lancet Oncol. 2015;16(13):1380‐1388.
Posted on
Previous Article
« T-DM1 does not improve safety or efficacy in HER-2 positive early breast cancer; favorable iDFS reported Next Article
Diastolic dysfunction novel risk factor for cognitive impairment »
« T-DM1 does not improve safety or efficacy in HER-2 positive early breast cancer; favorable iDFS reported Next Article
Diastolic dysfunction novel risk factor for cognitive impairment »
Table of Contents: ASCO 2020
Featured articles
COVID-19 & Telemedicine
COVID-19 and Cancer Consortium Registry: initial results
Oncology hospital-at-home model reduces hospitalizations, emergency department visits, and costs
Nurse-led telephone triage system reduces hospitalizations, helps patients manage symptoms at home
Melanoma
Adjuvant pembrolizumab: durable RFS for stage III melanoma
Adjuvant pembrolizumab: durable RFS for stage III melanoma
Pembrolizumab plus low-dose ipilimumab well tolerated after progression on PD1 antibody therapy
Toripalimab plus axitinib effective in metastatic mucosal melanoma
Breast & Ovarian Cancer
Advanced breast cancer: locoregional therapy does not improve OS
T-DM1 does not improve safety or efficacy in HER-2 positive early breast cancer; favorable iDFS reported
Maintenance olaparib improves OS in relapsed ovarian cancer with BRCA1/2 mutation
Combination pembrolizumab/chemo improves PFS in metastatic TNBC
Effect of veliparib with or without cisplatin in breast cancer: results of SWOG S1416
PHOEBE, a phase 3 trial comparing pyrotinib and lapatinib in HER2-positive metastatic breast cancer
BYLieve demonstrates efficacy of PIK3CA-directed treatment post CDK4/6-ihibition
Strategies emerge for chemotherapy de-escalation in HER2-positive breast cancer
Multiple Myeloma
Carfilzomib: no PFS benefit for multiple myeloma
Lung Cancer
ES-SCLC: tremelimumab + durvalumab + chemotherapy misses endpoint
Adjuvant osimertinib in NSCLC: practice changing ADAURA trial
ES-SCLC: pembrolizumab KEYNOTE-604 data
Second-line gemcitabine plus ramucirumab significantly improves overall survival
Tiragolumab and atezolizumab: ORR in NSCLC
MET-amplified advanced NSCLC responds well to MET inhibitor capmatinib
Genitourinary Cancer
Urothelial cancer: avelumab works as maintenance therapy
ARAMIS final OS and nmCRPC safety outcomes
Final survival results from phase 3 SPARTAN trial
Novel drug for kidney cancers/VHL patients
Primary analysis from IMvigor010, adjuvant atezolizumab in high risk muscle-invasive urothelial carcinoma
First randomised trial of Lu-PSMA in mCRPC progressing after docetaxel
Gastrointestinal Cancer
HER2-expressing metastatic colorectal cancer: trastuzumab deruxtecan
REGOMUNE: a phase 2 study combining regorafenib and avelumab
Cardiotoxicity: consider switching to S-1
Perioperative chemotherapy for resectable pancreatic ductal adenocarcinoma
Real-world data of sequential sorafenib followed by regorafenib in unresectable HCC
Paediatric Cancer
Sustained improvements in quality of life with larotrectinib
Promising first immunotherapy trial in placental trophoblastic tumours
Precision medicine for poor-prognosis paediatric patients
Related Articles
September 8, 2020
Advanced breast cancer: locoregional therapy does not improve OS
September 8, 2020
MET-amplified advanced NSCLC responds well to MET inhibitor capmatinib
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com